Siponimod (58, Figure 7) is a selective agonist of S1PR1 and SP1R5 that is currently in advanced Phase III clinical trials across 292 hospital clinics in 31 countries for treating secondary progressive multiple sclerosis (SPMS) [225]. This evidence concerns the gene S1PR1 and secondary progressive multiple sclerosis.